Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

References

• NayakRKDooseDRNairNPThe bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patientsJ Clin Pharmacol19872721441503680566
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• BransgroveLLKellyMWMovement disorders in patients treated with long-acting injectable antipsychotic drugsAm J Hosp Pharm19945178958997912473
   PubMedGoogle Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• GharabawiGMBossieCAZhuYAn assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term studySchizophr Res2005772–312913915913962
   PubMed Web of Science ®Google Scholar
• KraemerHCKupferDJSize of treatment effects and their importance to clinical research and practiceBiol Psychiatry2006591199099616368078
   PubMed Web of Science ®Google Scholar
• CitromeLKantrowitzJAntipsychotics for the treatment of schizophrenia: Likelihood to be helped or harmed, understanding proximal and distal benefits and risksExpert Rev Neurother2008871079109118590478
   PubMedGoogle Scholar
• CitromeLCompelling or irrelevant? Using number needed to treat can help decideActa Psychiatr Scand2008117641242918479317
   PubMed Web of Science ®Google Scholar
• StrausSEIndividualizing treatment decisions. The likelihood of being helped or harmedEval Health Prof200225221022412026754
   PubMed Web of Science ®Google Scholar
• CitromeLShow me the evidence: Using number needed to treatSouth Med J2007100988188417902287
   PubMed Web of Science ®Google Scholar
• Martinez-AranAVietaEChengappaKNGershonSMullenJPaulssonBReporting outcomes in clinical trials for bipolar disorder: A commentary and suggestions for changeBipolar Disord200810556657918657241
   PubMed Web of Science ®Google Scholar
• DottiABersaniGRubinoIAElliseoCDouble blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenicsRivista di Psichiatria1979145374383
   Google Scholar
• DavidAAdamsCEEisenbruchMDepot fluphenazine decanoate and enanthate for schizophreniaCochrane Database Syst Rev20051CD00030715674872
   PubMed Web of Science ®Google Scholar
• AdamsCEDavidAQuraishiSNDepot bromperidol decanoate for schizophreniaCochrane Database Syst Rev20043CD00171915266450
   PubMedGoogle Scholar
• QuraishiSNDavidABrasilMAAlheiraFVDepot haloperidol decanoate for schizophreniaCochrane Database Syst Rev19991CD001361
   Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• PandinaGLindenmayerJ-PLullJRandomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• EklundKForsmanAMinimal effective dose and relapse-double-blind trial: Haloperidol decanoate vs. placeboClin Neuropharmacol199114Suppl 2S7S121684310
   PubMed Web of Science ®Google Scholar
• HirschSRGaindRRohdePDStevensBCWingJKOutpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial. Report to the Medical Research Council committee on clinical trials in psychiatryBMJ1973158546336374571196
   PubMed Web of Science ®Google Scholar
• JolleyAGHirschSRMorrisonEMcRinkAWilsonLTrial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two yearsBMJ199030167568378422282421
   PubMed Web of Science ®Google Scholar
• OdejideOAAderounmuAFDouble-blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patientsJ Clin Psychiatry19824351951967076630
   PubMed Web of Science ®Google Scholar
• SmeraldiEBBelliniLRochiPVolonteMVVirziAAgugliaEBromperidol decanoate versus placebo in treating schizophrenia in the residual phaseNew Trends Exp Clin Psychiatry19906187198
   Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, an investigational long-acting injectable antipsychotic in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• GopalSHoughDXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol2010255245256
   Web of Science ®Google Scholar
• AltmanDGAndersenPKCalculating the number needed to treat for trials where the outcome is time to an eventBMJ199931972231492149510582940
   PubMed Web of Science ®Google Scholar
• BenderRCalculating confidence intervals for the number needed to treatControl Clin Trials200122210211011306148
   PubMedGoogle Scholar
• NewcombeRGInterval estimation for the difference between independent proportions: Comparison of eleven methodsStat Med19981788738909595617
   PubMed Web of Science ®Google Scholar
• WilsonEBProbable inference, the law of succession, and statistical inferenceJ Am Stat Assoc192722158209212
   Google Scholar
• SchlectmanEOdds ratio, relative risk, absolute risk reduction, and the number needed to treat – which of these should we use?Value Health20025543143612201860
   PubMed Web of Science ®Google Scholar
• CitromeLStroupTSSchizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?Int J Clin Pract200660893394016893436
   PubMed Web of Science ®Google Scholar
• KaragianisJRosenbluthMTohenMReviewing CATIE for clinicians: Balancing benefit and risk using evidence-based medicine toolsCurr Med Res Opin200723102551255717845743
   PubMed Web of Science ®Google Scholar
• StaufferVKaragianisJSuttonVNumber needed to treat (NNT) and number needed to harm (NNH) in randomized, blinded trials comparing olanzapine to other atypical antipsychotics for treatment of schizophreniaClin Schizophr Relat Psychoses200822136146
   Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCJohnMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet2009373657314119058842
   PubMed Web of Science ®Google Scholar
• TepperSJHaasJFPrevalence of tardive dyskinesiaJ Clin Psychiatry1979401250851640964
   PubMed Web of Science ®Google Scholar
• KaneJMTardive dyskinesisa rate with atypical antipsychotics in adults: Prevalence and incidenceJ Clin Psychiatry200465Suppl 9162015189107
   PubMed Web of Science ®Google Scholar
• CorrellCUSchenkEMTardive dyskinesia and new antipsychoticsCurr Opin Psychiatry200821215115618332662
   PubMed Web of Science ®Google Scholar
• TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: A reviewBr J Psychiatry Suppl2009195S13S1919880912
   PubMedGoogle Scholar
• CoppolaDLiuYGopalSLong-term safety, tolerability and pharmacokinetics of highest available dose of paliperidone palmitate: A one-year open-label study in patients with schizophrenia (submitted)
   Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol782010 [Epub ahead of print].
   Web of Science ®Google Scholar
• De HertMSchreursVSweersKTypical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart reviewSchizophr Res20081011–329530318299188
   PubMed Web of Science ®Google Scholar
• LeeEChowLYLeungCMMetabolic profile of first and second generation antipsychotics among Chinese patientsPsychiatry Res2011185345645820554016
   PubMed Web of Science ®Google Scholar
• TarriconeICasoriaMGozziBFMetabolic risk factor profile associated with use of second generation antipsychotics: A cross sectional study in a community mental health centreBMC Psychiatry200661116542430
   PubMed Web of Science ®Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract2010221623919886879
   PubMed Web of Science ®Google Scholar